Amorphous Cabozantinib Dispersion for Food-Effect-Free Oral Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cabozantinib formulations, such as CABOMETYX and COMETRIQ, require strict food intake restrictions and can cause adverse side effects due to food effects, leading to poor patient adherence and compliance.
Innovation Solution
Development of amorphous solid dispersions (ASDs) of cabozantinib with pharmaceutically acceptable polymers to enhance bioavailability and reduce dosage, minimizing food effect sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If immediate-release formulations of cabozantinib are used, then the drug can be administered orally with simple formulation, but the drug exhibits significant food effects requiring strict food intake restrictions
Solution Approach 1:
The patent transforms the drug formulation from immediate-release to amorphous solid dispersion, changing the physical state and release characteristics of cabozantinib. This parameter change eliminates the food effect while maintaining oral administration, resolving the contradiction between formulation simplicity and ease of operation regarding food restrictions
Solution Approach 2:
The patent creates a composite material system by dispersing cabozantinib in an amorphous matrix with specific polymers and excipients. This composite structure provides controlled release properties that eliminate food effects while maintaining oral dosing convenience, addressing both formulation simplicity and operational ease
2Reliability
If higher doses of cabozantinib are administered to achieve therapeutic effect, then the drug can effectively inhibit protein kinase activity, but the risk of adverse side effects increases
Solution Approach 1:
The patent changes the release rate parameter of cabozantinib by using amorphous solid dispersion technology. This results in controlled release that maintains therapeutic drug levels while avoiding peak concentrations that cause side effects, thus achieving reliable therapy with reduced harm
Solution Approach 2:
The controlled release mechanism provides feedback control of drug concentration in the body, maintaining levels within the therapeutic window. This prevents both sub-therapeutic doses and toxic peak levels, resolving the contradiction between efficacy and side effects
3Adaptability or versatility
If amorphous solid dispersions are developed to reduce food effect sensitivity, then bioavailability can be enhanced and dosing flexibility improved, but the formulation complexity increases
Solution Approach 1:
The amorphous solid dispersion formulation serves multiple functions simultaneously: it enhances bioavailability, eliminates food effects, provides controlled release, and improves stability. This multi-functionality justifies the increased formulation complexity by delivering comprehensive performance improvements
Data Source
AI summary
Amorphous solid dispersions of the protein kinase inhibitor cabozantinib. The amorphous solid dispersions exhibit chemical and physical stability under stressed conditions. The amorphous solid dispersions may be suitable for use in pharmaceutical compositions for administration to human subjects or patients.